ArticleWorld journal of gastrointestinal pathophysiology2025
Dynamics of tissue and fecal microbiota in active Crohn's disease and their ability to predict disease state.
Article in World journal of gastrointestinal pathophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSimultaneous assessment of gut microbiota in stool and tissue samples is crucial for a better understanding of their role in Crohn's disease (CD), yet most reports have focused on fecal microbiota alone. Additionally, gut microbiota may serve as a clinically useful diagnostic biomarker of CD although data on this is limited.
aimTo evaluate gut microbiota in tissue and stool samples in patients with active CD to understand the structure and function compared to healthy controls (HC). We also assessed their utility as a diagnostic biomarker of CD.
methodsAdult patients with active CD and HC were prospectively recruited for this study. The clinical and investigation details were recorded. Rectal mucosal biopsy and stool samples were obtained to assess the bacterial population. DNA was extracted, the V3-V4 region of the 16S rRNA gene was amplified, and library preparation was done and sequenced on the Illumina MiSeq platform. The bacterial diversity, composition, dysbiosis, predicted function, and predictors of disease state were estimated using the QIIME 2 pipeline and R packages.
resultsWe recruited 66 patients with CD (age 39.7 ± 11.1 years, 65.2% males) and 69 HC. Comparison of tissue with fecal microbiota in active CD showed significant differences in composition and predicted function. Both tissue and fecal microbiota from active CD showed reduced microbial diversity and compositional differences compared to HC, and disease state was a key determinant of bacterial population. Differences (CD
conclusionGut microbial characteristics revealed significant structural and functional differences between CD and HC in both tissue and stool. Tissue bacteria performed well as a microbial biomarker for clinical diagnosis of CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.